Cargando…

Cavernomas: Outcomes after gamma-knife radiosurgery in Iran

BACKGROUND: Treatment of cavernomas remains a challenge in surgically inaccessible regions. The purpose of this study was to evaluate outcomes after gamma-knife surgery (GKS) for these patients. MATERIALS AND METHODS: A retrospective review of 100 patients treated between 2003 and 2011 was conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Azimi, Parisa, Shahzadi, Sohrab, Bitaraf, Mohammad Ali, Azar, Maziar, Alikhani, Mazdak, Zali, Alireza, Sadeghi, Sohrab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352634/
https://www.ncbi.nlm.nih.gov/pubmed/25767582
http://dx.doi.org/10.4103/1793-5482.151515
Descripción
Sumario:BACKGROUND: Treatment of cavernomas remains a challenge in surgically inaccessible regions. The purpose of this study was to evaluate outcomes after gamma-knife surgery (GKS) for these patients. MATERIALS AND METHODS: A retrospective review of 100 patients treated between 2003 and 2011 was conducted in order to evaluate hemorrhage rates, complications, radiation effects after GKS. Dosage at the tumor margin was stratified into two groups: those that received ≤13 Gy; and those who received >13 Gy. The demographic and clinical characteristics of patients including age, gender, and hemorrhage rates were extracted from care records. RESULTS: The median age was 32.5 years (ranging from 15 to 79). 44% were female. The median follow-up time was 42.2 months (ranging from 24 to 90). The median volume of the lesions was 1050.0 mm(3) (ranging from 112.0 to 4100.0) before GKS. A reduction of 27.5% in median size of cavernomas was achieved at the last follow-up. There was 12% treatment-related morbidity after GKS. The hemorrhage rate in the first 2 years after GKS was 4.1% and 1.9% thereafter. There was no mortality due to GKS, and 93 patients were alive at the last follow-up. The radiation-related complication developed with marginal dose 13 Gy. CONCLUSION: The GKS for cavernomas appears to be a safe and beneficial in carefully selected patients. Low-dose GKS may be effective for the management of cavernous malformations.